Ipsen

Ipsen takes €669M hit as palovarotene's prospects wither
Ipsen takes €669M hit as palovarotene's prospects wither
Fierce Biotech
Ipsen
palovarotene
Flag link:
Top Companies in Pharm Country Ranked by Revenue
Top Companies in Pharm Country Ranked by Revenue
BioSpace
Connecticut
New York
New Jersey
Pennsylvania
Rhode Island
Merck
Bristol-Myers Squibb
Regeneron
Ipsen
Ovid Therapeutics
Codagenix
Flag link:
Ipsen’s quick fix backfires
Ipsen’s quick fix backfires
EP Vantage
Ipsen
bone disease
palovarotene
Flag link:
Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns
Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns
Bloomberg
Ipsen
Somatuline
FDA
fibrodysplasia ossificans progressiva
osteochondromas
Flag link:
Ipsen doubles down on rare bone disease
Ipsen doubles down on rare bone disease
EP Vantage
Ipsen
FOP
BLU-782
Blueprint Medicines
Clementia Pharmaceuticals
Flag link:
FDA approves Ipsen’s Dysport to treat upper limb spasticity in children
FDA approves Ipsen’s Dysport to treat upper limb spasticity in children
Pharmaceutical Business Review
Ipsen
Dysport
upper limb spasticity
FDA
Flag link:
Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer
Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer
Pharmaceutical Business Review
Ipsen
Servier
liposomal irinotecan
pancreatic cancer
Flag link:
Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia
Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia
Endpoints
M&A
Ipsen
Clementia Pharmaceuticals
Rare Diseases
Flag link:
FDA approves Cabometyx for liver cancer
FDA approves Cabometyx for liver cancer
BioCentury
Exelixis
Ipsen
Cabometyx
liver cancer
FDA
Flag link:
With New HQ, Ipsen to Rapidly Expand North American Presence
With New HQ, Ipsen to Rapidly Expand North American Presence
BioSpace
Ipsen
Kendall Square
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
CP WIre
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
CP Wire
Exelixis
Cabometyx
Takeda
Canada
Japan
Ipsen
renal cell carcinoma
Flag link:
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
Exelixis
Ipsen
Cabometyx
Flag link:
Relocating its US HQ to Boston, French pharma Ipsen to add 250 jobs
Relocating its US HQ to Boston, French pharma Ipsen to add 250 jobs
Endpoints
biotech
Boston
Kendall Square
Ipsen
hirings
Flag link:
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Exelixis
Ipsen
Cabometyx
advanced renal cell carcinoma
renal cell carcinoma
Flag link:
Ipsen focuses on oncology to keep growing
Ipsen focuses on oncology to keep growing
GoInPharma
Ipsen
oncology
Xermelo
kidney cancer
Flag link:
Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug
Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug
Mass Device
Ipsen
gastroenteropancreatic neuroendocrine tumor
Somatuline
Flag link:
Sanofi Sells 5 Over-the-Counter Drugs for $88M
Sanofi Sells 5 Over-the-Counter Drugs for $88M
Investopedia
Sanofi
OTC
M&A
Ipsen
Flag link:
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal
Yahoo/Reuters
Ipsen
France
Merrimack Pharmaceuticals
pancreatic cancer
Onivyde
Flag link:

Pages